Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis; ...

ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and ...

Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling ...

9 Because of its potential association with systemic diseases and malignancies, it is recommended that patients with spiny keratoderma undergo appropriate screening for underlying diseases.

Detailed price information for Quoin Pharmaceuticals Ltd ADR (QNRX-Q) from The Globe and Mail including charting and trades.

Key clinical features included extensive reticulate hyperpigmentation, palmoplantar keratoderma, and dental anomalies. Rarely reported findings, such as cerebellar fissures and generalized osteopenia, ...

Detailed price information for Quoin Pharmaceuticals Ltd ADR (QNRX-Q) from The Globe and Mail including charting and trades.

Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling ...

The purpose of this study is to assess the clinical efficacy and safety of upadacitinib in patients with refractory palmoplantar pustulosis who have not responded to conventional treatments (e.g., ...